Navigation auf uzh.ch
Navigation auf uzh.ch
The innovative team at Molecular Partners AG has succeeded in developing an effective drug for people suffering from Covid-19. This pharmaceutical company is a spin-off of the Department of Biochemistry of the Faculty of Mathematics and Natural Sciences of the University of Zurich: the technology was originally developed in the laboratory of Prof. Andreas Plückthun.
Tuesday, 08.02.2022, 12 p.m. to 1 p.m.
In their public lecture, Prof. Andreas Plückthun, Professor for Biochemistry at the University of Zurich and co-founder of Molecular Partners, together with Dr. Michael Tobias Stumpp, Chief Operating Officer, member of the Management Board and co-founder of Molecular Partners AG, will provide insights into the history of the development of an innovative technology and of the promising drug, now licensed to Novartis AG.
General Information
Date: Tuesday, 08.02.2022
Time: 12 p.m. to 1 p.m.
Due to the current situation, the lecture will be held virtually.
Registration https://uzh.zoom.us/meeting/register/u5YpcuCsqTgsE9YdClPhblI4b4G1Q5qUbMQP
Media release Molecular Partners (10.01.2022) https://investors.molecularpartners.com/news-releases/news-release-details/molecular-partners-and-novartis-report-positive-topline-data
Selection of reports in Media (German only)
10.01.2022, Finanz und Wirtschaft, Novartis kauft Moleculars Coronamedikament
12.01.2022 UZH News, Erfolgreiche Innovation, «Wir haben einen stabilen Wirkstoff geschaffen»
